preclinical AD
-
ADNI, Alzheimer’s disease, amyloid, APOE, APOE-e4, blood biomarker, Brain, cognition, donanemab, Drugs, genetics, lecanemab, longitudinal cohort, mild cognitive impairment, Neurodegenerative Diseases, neuroscience, p-tau217, preclinical ADPlasma p-tau217 Blood Test Predicts Alzheimer’s Risk 1.5x Stronger in APOE-e4
Until recently, Alzheimer’s pathology could only be confirmed in living patients via…
